SCHEMBL717052

SCHEMBL717052

COC(=O)CNCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
RECQL P46063 1/20 0.50
ATM Q13315 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PPID Q08752 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 3/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HPGD P15428 2/20 0.47
SPHK2 Q9NRA0 1/20 0.47
SPHK1 Q9NYA1 1/20 0.47
TP53 P04637 1/20 0.46
GLA P06280 1/20 0.46
MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19401273 1.00 MEN1 (0.50) MEN1KMT2ARECQLATMSMN1; SMN2
Hydrochloric Acid SCHEMBL2840965 0.98 MEN1 (0.49) MEN1KMT2ARECQLATMSMN1; SMN2
SCHEMBL1997225 0.90 ALDH1A1 (0.51) MEN1KMT2AATMSMN1; SMN2ALDH1A1
SCHEMBL3498807 0.86 BCHE (0.67) MEN1KMT2ASMN1; SMN2SPHK2SPHK1
SCHEMBL23164929 0.84 ALDH1A1 (0.53) MEN1KMT2ARECQLATMSMN1; SMN2
SCHEMBL75205 0.84 PPID (0.69) RECQLSMN1; SMN2PPIDALDH1A1MAPT
SCHEMBL27530968 0.83 SPHK2 (0.49) MEN1KMT2ARECQLSMN1; SMN2PPID
SCHEMBL6811685 0.83 KMT2A (0.50) MEN1KMT2AATMSMN1; SMN2ALDH1A1
SCHEMBL1279312 0.83 CA1 (0.49) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL28958210 0.83 KMT2A (0.50) MEN1KMT2AATMSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115583903-B Method for rapidly preparing racecadotril 湖北广辰药业有限公司 2024-05-28 CN claimed
CN-115583903-A Method for rapidly preparing racecadotril 湖北广辰药业有限公司 2023-01-10 CN claimed
EP-3219335-B1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO CORP (JP) 2018-12-19 EP claimed
EP-3219335-A1 COATING COMPOSITION AND MEDICAL DEVICE Terumo Kabushiki Kaisha (JP) 2017-09-20 EP claimed
US-20170143663-A1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO KABUSHIKI KAISHA (JP) 2017-05-25 US claimed
EP-2813250-B1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO CORP (JP) 2017-05-03 EP claimed
US-9603974-B2 Coating composition and medical device TERUMO KABUSHIKI KAISHA (JP) 2017-03-28 US claimed
CN-105797218-A Coating composition and medical device 泰尔茂株式会社 2016-07-27 CN claimed
CN-104203297-B Coating composition and medical device TERUMO CORP. (JP) 2016-04-06 CN claimed
US-20150056265-A1 COATING COMPOSITION AND MEDICAL DEVICE TERUMO KABUSHIKI KAISHA (JP) 2015-02-26 US claimed
EP-2813250-A1 COATING COMPOSITION AND MEDICAL DEVICE Terumo Kabushiki Kaisha (JP) 2014-12-17 EP claimed
CN-104203297-A Coating composition and medical device TERUMO CORP 2014-12-10 CN claimed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 US disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 EP disclosed
WO-2025064869-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CIDARA THERAPEUTICS, INC. (US) 2025-03-27 WO disclosed
WO-2025045106-A1 PI3Kα INHIBITOR AND USE THEREOF 郑州同源康医药有限公司 2025-03-06 WO disclosed
EP-0235575-A1 Novel phenolic thioethers as inhibitors of 5-lipoxygenase G.D. Searle & Co. (US) 1987-09-09 EP disclosed
US-4663319-A LIVER DISORDERS TANABE SEIYSKU CO., LTD. (JP) 1987-05-05 US disclosed
EP-0205280-A2 Tetrahydroimidazoquinazolinone cardiac stimulants Pfizer Limited (GB) 1986-12-17 EP disclosed
EP-0149534-A2 Novel thioketene derivatives and process for the preparation thereof Tanabe Seiyaku Co., Ltd. (JP) 1985-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170143663-A1 COATING COMPOSITION AND MEDICAL DEVICE SLC6A19, SLC7A1, SLC38A7 MEN1 1761/4885KMT2A 1756/4885RECQL 3358/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B MEN1 2494/4885KMT2A 1971/4885RECQL 2204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.